Top Markets
Coin of the day
Antisense Therapeutics Limited Antisense Therapeutics Limited

Antisense Therapeutics Limited

ANP
株式のランク #33642
Antisense Therapeutics Limited, an Australian company headquartered in Toorak... Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
株価
$0.03702159
最終同期: 2024-01-29
時価総額
$7.21M
変化(1日)
-3.08%
変化(1年)
0.00%
AU
取引 Antisense Therapeutics Limited (ANP)

カテゴリー

Antisense Therapeutics Limited(ANP)の株式分割履歴
Antisense Therapeutics Limited株(シンボル:ANP)は合計で0回の株式分割を実施しました。
最新の株式分割はAug 17, 2026に行われました。
Aug 17, 2026より前に購入されたANP株は、現在0ANP株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割